Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.

Autor: Jain R; Department(s) and institution(s) - Department of Blood Bank, Goa Medical College, Goa 403202, India. Electronic address: romeshgolu@gmail.com., Mallya MV; Department(s) and institution(s) - Department of Blood Bank, Goa Medical College, Goa 403202, India., Amoncar S; Department(s) and institution(s) - Department of Blood Bank, Goa Medical College, Goa 403202, India., Palyekar S; Department(s) and institution(s) - Department of Blood Bank, Goa Medical College, Goa 403202, India., Adsul HP; Department(s) and institution(s) - Department of Blood Bank, Goa Medical College, Goa 403202, India., Kumar R; Department(s) and institution(s) - Department of Transfusion medicine, Main Blood Bank, Ansari Nagar, AIIMS, New Delhi 110029, India., Chawla S; Department(s) and institution(s) - Department of Community Medicine, Pt. JLNGMCH, Chamba, Himachal Pradesh, India.
Jazyk: angličtina
Zdroj: Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine [Transfus Clin Biol] 2022 Feb; Vol. 29 (1), pp. 60-64. Date of Electronic Publication: 2021 Jul 22.
DOI: 10.1016/j.tracli.2021.07.004
Abstrakt: Background and Objectives: Seroprevalence estimation of COVID-19 is quite necessary for controlling the transmission of SARS-CoV-2 infection. Seroprevalence rate in recovered COVID-19 patients help us to identify individual with anti-SARS-CoV-2 antibodies and its protective nature. The objective of present study was to evaluate seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral reasons.
Materials and Methods: A total 400 potential convalescent plasma donors were enrolled over five-month period for this prospective study. Inclusion criteria were lab confirmed COVID-19 recovered patients and 14 days of symptoms free period. All prospective plasmapheresis donors were tested for IgG SARS-CoV-2 antibody through chemiluminescent microparticle immunoassay, CBC, serum protein, blood grouping along with other required test for normal blood donation as per Drugs & Cosmetics Act. After pre donation testing and medical examination if donor was found to be ineligible for plasmapheresis was deferred. Seroprevalence rate was calculated by positive IgG antibody test results among the potential plasma donors.
Results: Seroprevalence rate was 87% for IgG SARS-CoV-2 antibodies in prospective convalescent plasma donors (recovered COVID-19 patients). There was no significant difference in seroprevalence rate between different sub-groups with respect to gender, age, blood groups, Rh factor, mode of treatment, day of Ab testing and repeat plasma donation. Most common reason for their deferral was absent IgG SARS-CoV-2 antibodies (13%) followed by absenteeism of eligible screen donors (6.7%), low Hb (1.7%) and poor veins for plasmapheresis (1.7%). Till five-month study period none of the plasmapheresis develop symptoms of reinfection with COVID-19.
Conclusion: In all, 13% recovered patients did not develop IgG antibodies after SARS-CoV-2 infection. SARS-CoV-2 IgG antibodies persist for quite some time and are protective against reinfection. More long-term serology studies are needed to understand better antibody response kinetics and duration of persistence of IgG antibodies.
(Copyright © 2021 Société française de transfusion sanguine (SFTS). Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: